Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Anacor Pharmaceuticals Announces Collaboration to Apply Boron Chemistry Technology to Identify New Medicines for the Treatment of Malaria

By Pharmaceutical Processing | April 26, 2010

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor’s novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.

“Anacor is pleased to be working with MMV in an effort to discover and develop promising new therapeutics for malaria,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals, Inc. “Anacor will continue to pursue these research and development activities in neglected diseases with the world’s leading not-for-profit organizations where we believe that our boron chemistry platform and expertise shows promising activity.”

“This agreement being announced in conjunction with World Malaria Day 2010 underscores our commitment to seek innovative scientific approaches that will provide the next generation of front line malaria therapeutics,” says Dr. Tim Wells, Chief Scientific Officer of MMV. “Malaria kills over 850,000 people annually, with the majority of victims being children under five and pregnant women. There is a critical need for safe and easy to use medications to thwart growing resistance to current drugs in this most vulnerable population. We hope that this collaboration with Anacor will lead us to effective new treatments for this devastating disease.”

 

Related Articles Read More >

GSK
GSK invests another $800M in Pennsylvania site expansions
This is a BD image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.
BD to invest billions in U.S. manufacturing
Diverse factory workers in yellow PPE suits checking production data with clipboard in modern industrial facility, Quality control inspector wearing masks and hairnets working in food or pharma plant
ISO 9001, 14001 and 45001 revisions: What changes and when to start
Artis BioSolutions announces new center of excellence in Spain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE